Literature DB >> 20711592

Early endoscopy in systemic sclerosis without gastrointestinal symptoms.

Rene Thonhofer1, Cornelia Siegel, Markus Trummer, Winfried Graninger.   

Abstract

Investigation into the upper GI-tract of patients suffering from systemic sclerosis [SSc] and mixed connective tissue disease [MCTD] without symptoms of GI-tract involvement early in the course of the disease to diagnose inflammatory and motility disorders. We retrospectively analysed patients with SSc and MCTD who underwent oesophago-gastro-duodenoscopy [OGD] within a year of the first diagnosis. Patients with a Rodnan skin score above 5, proton pump inhibitors and treatment regimes potentially harmful to the mucosa of the upper GI-tract were excluded. Mucosal damage of the oesophagus was classified according to the Los Angeles Classification. Oesophageal dysmotility was assessed during OGD and confirmed by video cineradiography. A total of thirteen patients with SSc and six with MCTD fulfilled the inclusion criteria. OGD revealed reflux-oesophagitis in 77%, dysmotility of the distal oesophagus in 85%, gastritis in 92% [31% erosive gastritis] and Helicobacter pylori positivity in 38% of our patients suffering from SSc. Patients with MCTD showed features of reflux-oesophagitis, dysmotility of the distal oesophagus, gastritis and dysmotility of the stomach in 0.6%. In all thirteen patients with SSc, significant pathology of the upper GI-tract was found. The results of this study might indicate that OGD should be performed early in patients diagnosed with SSc, even if they do not report typical symptoms. An early diagnose of GI involvement might be followed by an effective therapy and therefore subsequently may improve the prognosis.

Entities:  

Mesh:

Year:  2010        PMID: 20711592     DOI: 10.1007/s00296-010-1595-y

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  27 in total

1.  SCLERODERMA OF THE ESOPHAGUS. A CORRELATION OF HISTOLOGIC AND PHYSIOLOGIC FINDINGS.

Authors:  W L TREACY; A H BAGGENSTOSS; C H SLOCUMB; C F CODE
Journal:  Ann Intern Med       Date:  1963-09       Impact factor: 25.391

2.  The endoscopic assessment of esophagitis: a progress report on observer agreement.

Authors:  D Armstrong; J R Bennett; A L Blum; J Dent; F T De Dombal; J P Galmiche; L Lundell; M Margulies; J E Richter; S J Spechler; G N Tytgat; L Wallin
Journal:  Gastroenterology       Date:  1996-07       Impact factor: 22.682

3.  Oesophageal mucosal involvement in patients with systemic sclerosis receiving proton pump inhibitor therapy.

Authors:  I Marie; P Ducrotte; P Denis; M F Hellot; H Levesque
Journal:  Aliment Pharmacol Ther       Date:  2006-12       Impact factor: 8.171

Review 4.  Esophageal involvement in scleroderma: gastroesophageal reflux, the common problem.

Authors:  Stavros K Ntoumazios; Paraskevi V Voulgari; Konstantinos Potsis; Evagelos Koutis; Niki Tsifetaki; Dimitrios A Assimakopoulos
Journal:  Semin Arthritis Rheum       Date:  2006-10-11       Impact factor: 5.532

5.  Gastrointestinal manifestations in Hungarian scleroderma patients.

Authors:  Szilvia Szamosi; Zoltán Szekanecz; Gabriella Szucs
Journal:  Rheumatol Int       Date:  2006-06-13       Impact factor: 2.631

6.  Omeprazole triple therapy versus omeprazole quadruple therapy for healing duodenal ulcer and eradication of Helicobacter pylori infection: a 24-month follow-up study.

Authors:  Gerassimos J Mantzaris; Kalliopi Petraki; Emmanuel Archavlis; Pericles Amberiadis; Panagiotis Christoforidis; Demetrius Kourtessas; Efterpi Chiotakakou; George Triantafyllou
Journal:  Eur J Gastroenterol Hepatol       Date:  2002-11       Impact factor: 2.566

7.  Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients.

Authors:  D Alarcón-Segovia; M H Cardiel
Journal:  J Rheumatol       Date:  1989-03       Impact factor: 4.666

8.  Characteristics of patients with early systemic sclerosis and severe gastrointestinal tract involvement.

Authors:  Emi Nishimagi; Akiko Tochimoto; Yasushi Kawaguchi; Takashi Satoh; Masataka Kuwana; Kae Takagi; Hisae Ichida; Tokiko Kanno; Makoto Soejima; Sayumi Baba; Naoyuki Kamatani; Masako Hara
Journal:  J Rheumatol       Date:  2007-10       Impact factor: 4.666

Review 9.  Autoantibodies in the diagnosis of systemic rheumatic diseases.

Authors:  C A von Mühlen; E M Tan
Journal:  Semin Arthritis Rheum       Date:  1995-04       Impact factor: 5.532

Review 10.  The role of capillaroscopy in differentiation of primary and secondary Raynaud's phenomenon in rheumatic diseases: a review of the literature and two case reports.

Authors:  Sevdalina Nikolova Lambova; Ulf Müller-Ladner
Journal:  Rheumatol Int       Date:  2009-06-23       Impact factor: 2.631

View more
  27 in total

1.  Successful laparoscopic Nissen fundoplication in a patient with mixed connective tissue disease with a short esophagus: report of a case.

Authors:  Kiyokazu Nakajima; Tsuyoshi Takahashi; Shuji Takiguchi; Hiroshi Miyata; Makoto Yamasaki; Yukinori Kurokawa; Masaki Mori; Yuichiro Doki
Journal:  Surg Today       Date:  2013-09-10       Impact factor: 2.549

2.  Management of gastrointestinal involvement in scleroderma.

Authors:  Vivek Nagaraja; Zsuzsanna H McMahan; Terri Getzug; Dinesh Khanna
Journal:  Curr Treatm Opt Rheumatol       Date:  2015-03-01

Review 3.  Review article: pathogenesis and clinical manifestations of gastrointestinal involvement in systemic sclerosis.

Authors:  S Kumar; J Singh; S Rattan; A J DiMarino; S Cohen; S A Jimenez
Journal:  Aliment Pharmacol Ther       Date:  2017-02-09       Impact factor: 8.171

4.  Validation of Serbian version of UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in 104 patients with systemic sclerosis.

Authors:  Ana Zekovic; Nemanja Damjanov
Journal:  Rheumatol Int       Date:  2017-03-07       Impact factor: 2.631

Review 5.  Gastrointestinal and Hepatic Disease in Systemic Sclerosis.

Authors:  Tracy M Frech; Diane Mar
Journal:  Rheum Dis Clin North Am       Date:  2018-02       Impact factor: 2.670

Review 6.  Gastrointestinal manifestations of scleroderma: recent progress in evaluation, pathogenesis, and management.

Authors:  Genevieve Gyger; Murray Baron
Journal:  Curr Rheumatol Rep       Date:  2012-02       Impact factor: 4.592

7.  Increased inspiratory esophagogastric junction pressure in systemic sclerosis: an add-on to antireflux barrier.

Authors:  Miguel Ângelo Nobre e Souza; Patrícia Carvalho Bezerra; Rivianny Arrais Nobre; Esther Studart da Fonseca Holanda; Armênio Aguiar dos Santos
Journal:  World J Gastroenterol       Date:  2015-02-21       Impact factor: 5.742

8.  Clinical Assessment of Gastrointestinal Involvement in Patients with Systemic Sclerosis.

Authors:  Timothy Kaniecki; Tsion Abdi; Zsuzsanna H McMahan
Journal:  Med Res Arch       Date:  2020-10-29

9.  Abnormal esophageal acid exposure on high-dose proton pump inhibitor therapy is common in systemic sclerosis patients.

Authors:  E K Stern; D A Carlson; S Falmagne; A D Hoffmann; M Carns; J E Pandolfino; M Hinchcliff; D M Brenner
Journal:  Neurogastroenterol Motil       Date:  2017-11-06       Impact factor: 3.598

Review 10.  Points to consider for clinical trials of the gastrointestinal tract in systemic sclerosis.

Authors:  Daniel E Furst; Yolanda Braun-Moscovic; Dinesh Khanna
Journal:  Rheumatology (Oxford)       Date:  2017-09-01       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.